Hologic (NASDAQ:HOLX) had its price target reduced by analysts at Barclays from $51.00 to $43.00 in a note issued to investors on Thursday, BenzingaRatingsTable reports. The brokerage presently has an “equal weight” rating on the medical equipment provider’s stock. Barclays‘s price objective would indicate a potential upside of 29.28% from the company’s previous close.
Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. decreased their target price on shares of Hologic from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday, March 17th. Needham & Company LLC upped their price target on shares of Hologic from $57.00 to $62.00 and gave the company a “buy” rating in a report on Monday, January 13th. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Thursday, March 5th. BTIG Research reaffirmed a “buy” rating and issued a $54.00 price target on shares of Hologic in a report on Thursday, January 30th. Finally, Piper Sandler upped their price target on shares of Hologic from to in a report on Thursday, January 30th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company’s stock. Hologic presently has a consensus rating of “Hold” and an average price target of $55.00.
Shares of HOLX stock traded up $1.00 on Thursday, hitting $33.26. The stock had a trading volume of 140,574 shares, compared to its average volume of 3,655,975. The firm has a market capitalization of $8.28 billion, a price-to-earnings ratio of 36.17, a P/E/G ratio of 1.55 and a beta of 0.90. The stock’s 50 day moving average is $45.71 and its 200-day moving average is $49.47. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.20 and a current ratio of 1.57. Hologic has a 52-week low of $26.49 and a 52-week high of $55.25.
In other Hologic news, General Counsel John M. Griffin sold 19,624 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $52.86, for a total transaction of $1,037,324.64. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Karleen Marie Oberton sold 16,348 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $51.73, for a total transaction of $845,682.04. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of the business. FMR LLC increased its holdings in shares of Hologic by 1.9% in the 4th quarter. FMR LLC now owns 13,715,204 shares of the medical equipment provider’s stock worth $716,070,000 after acquiring an additional 254,580 shares during the period. State Street Corp increased its holdings in shares of Hologic by 2.2% in the 4th quarter. State Street Corp now owns 11,447,014 shares of the medical equipment provider’s stock worth $597,649,000 after acquiring an additional 240,985 shares during the period. Geode Capital Management LLC increased its holdings in shares of Hologic by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 5,021,903 shares of the medical equipment provider’s stock worth $261,777,000 after acquiring an additional 261,317 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Hologic by 0.5% in the 4th quarter. Nuveen Asset Management LLC now owns 3,189,783 shares of the medical equipment provider’s stock worth $166,539,000 after acquiring an additional 16,769 shares during the period. Finally, Norges Bank acquired a new stake in shares of Hologic in the 4th quarter worth about $153,506,000. 95.15% of the stock is currently owned by institutional investors.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.